{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:00:27Z","timestamp":1761843627737},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1097\/jcp.0b013e318033bd4a","type":"journal-article","created":{"date-parts":[[2007,3,19]],"date-time":"2007-03-19T07:57:26Z","timestamp":1174291046000},"page":"126-134","source":"Crossref","is-referenced-by-count":16,"title":["Outcomes for Latin American Versus White Patients Suffering From Acute Mania in a Randomized, Double-Blind Trial Comparing Olanzapine and Haloperidol"],"prefix":"10.1097","volume":"27","author":[{"given":"Jorge M.","family":"Tamayo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Mazzotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio","family":"Tohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wagner F.","family":"Gattaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Zapata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 J.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo D.","family":"Fahrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana M.","family":"Gonz\u00e1lez-Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean M.","family":"Azorin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Rovner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Bonett-Perrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"suppl 11","key":"R1-2-20210128","first-page":"12","article-title":"The role of neuroleptics in manic-depressive illness.","volume":"49","author":"Kane","year":"1988","journal-title":"J Clin Psychiatry"},{"key":"R2-2-20210128","first-page":"125","article-title":"Neurolepticos na face mania do disturbio do humor Neuroleptics in the manic phase of mood disorder.","volume":"38","author":"Bechelli","year":"1989","journal-title":"J Bras Psiquiatr"},{"key":"R3-2-20210128","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0447.1998.tb10020.x","article-title":"Drug treatment of mania: a critical review.","volume":"97","author":"Licht","year":"1998","journal-title":"Acta Psychiatr Scand"},{"key":"R4-2-20210128","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4088\/JCP.v61n0116","article-title":"High exposure to neuroleptics in bipolar patients: a retrospective review.","volume":"61","author":"Brotman","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R5-2-20210128","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00004850-199100610-00006","article-title":"Tardive dyskinesia in bipolar affective disorder: a catchment area study.","volume":"6","author":"Hunt","year":"1991","journal-title":"Int Clin Psychopharmacol"},{"key":"R6-2-20210128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1192\/bjp.187.3.235","article-title":"Effectiveness of aripiprazole v. haloperidol in acute bipolar mania.","volume":"187","author":"Vieta","year":"2005","journal-title":"Br J Psychiatry"},{"key":"R7-2-20210128","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/archpsyc.60.12.1218","article-title":"A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania.","volume":"60","author":"Tohen","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R8-2-20210128","first-page":"176","article-title":"Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial.","volume":"21","author":"Segal","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"R9-2-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.euroneuro.2004.06.003","article-title":"Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol.","volume":"15","author":"Smulevich","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"R11-2-20210128","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/BF01312605","article-title":"Mental health status among Puerto Ricans, Mexican Americans, and non-Hispanic whites.","volume":"20","author":"Shrout","year":"1992","journal-title":"Am J Community Psychol"},{"key":"R12-2-20210128","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/archpsyc.60.6.637","article-title":"Diagnostic patterns in Latino, African American, and European American psychiatric patients.","volume":"60","author":"Minsky","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R15-2-20210128","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00004714-200108000-00004","article-title":"Olanzapine as alternative therapy for patients with haloperidol-induced extra pyramidal symptoms: results of a multicenter collaborative trial in Latin America.","volume":"21","author":"Costa e Silva","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R16-2-20210128","first-page":"131","article-title":"Pasaje de pacientes psicoticos de Haloperidol a Olanzapina. Un estudio multicentrico abierto de Seguridad y Eficacia.","volume":"47","author":"Rovner","year":"2001","journal-title":"Acta Psiquiatr Psicol Am Lat"},{"key":"R18-2-20210128","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00004850-200209000-00003","article-title":"Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status.","volume":"17","author":"Shi","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"key":"R19-2-20210128","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0165-1781(97)00123-6","article-title":"Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP.","volume":"73","author":"Spearing","year":"1997","journal-title":"Psychiatry Res"},{"key":"R21-2-20210128","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity, and sensitivity.","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"},{"key":"R22-2-20210128","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.2044-8260.1967.tb00530.x","article-title":"Development of a rating scale for primary depressive illness.","volume":"6","author":"Hamilton","year":"1967","journal-title":"Br J Soc Clin Psychol"},{"key":"R23-2-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects.","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand"},{"key":"R24-2-20210128","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia.","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"R26-2-20210128","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archpsyc.1991.01810330075011","article-title":"Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence.","volume":"48","author":"Frank","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"R27-2-20210128","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1176\/appi.psychotherapy.1982.36.4.505","article-title":"Pharmacotherapy of Hispanic depressed patients: clinical observations.","volume":"36","author":"Marcos","year":"1982","journal-title":"Am J Psychother"},{"key":"R28-2-20210128","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.","volume":"49","author":"Farde","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"R29-2-20210128","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1600-0447.1994.tb01591.x","article-title":"D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects.","volume":"90","author":"Scherer","year":"1994","journal-title":"Acta Psychiatr Scand"},{"key":"R30-2-20210128","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.","volume":"157","author":"Kapur","year":"2000","journal-title":"Am J Psychiatry"},{"key":"R31-2-20210128","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics? a new hypothesis.","volume":"158","author":"Kapur","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R32-2-20210128","first-page":"49","article-title":"Antidepressant agents: a cross cultural study.","volume":"16","author":"Escobar","year":"1980","journal-title":"Psychopharmacol Bull"},{"key":"R33-2-20210128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1176\/ps.49.2.239","article-title":"Ethnic differences in response to fluoxetine in a controlled trial with depressed HIV-positive patients.","volume":"49","author":"Wagner","year":"1998","journal-title":"Psychiatr Serv"},{"key":"R34-2-20210128","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00004850-199911000-00001","article-title":"Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison.","volume":"14","author":"Versiani","year":"1999","journal-title":"Int Clin Psychopharmacol"},{"key":"R35-2-20210128","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/da.1027","article-title":"Open trial of nefazodone among Hispanics with major depression: efficacy, tolerability, and adherence issues.","volume":"13","author":"Sanchez-Lacay","year":"2001","journal-title":"Depress Anxiety"},{"key":"R36-2-20210128","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/clpt.1992.156","article-title":"Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability.","volume":"52","author":"Lindholm","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"R37-2-20210128","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0009-9236(99)70037-8","article-title":"Population distribution and effects on drug metabolism of a genetic variant in the 5 promoter region of CYP3A4.","volume":"66","author":"Ball","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"R38-2-20210128","first-page":"217","article-title":"Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations.","volume":"9","author":"Jorge","year":"1999","journal-title":"Pharmacogenetics"},{"key":"R39-2-20210128","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1358\/mf.2000.22.9.802286","article-title":"Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population.","volume":"22","author":"Isaza","year":"2000","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"R40-2-20210128","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1067\/mcp.2001.120675","article-title":"CYP2D6 polymorphism in a Mexican American population.","volume":"70","author":"Mendoza","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"R41-2-20210128","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1067\/mcp.2002.127398","article-title":"Cytochrome P450 2E1 and 3A activities do not differ between Mexicans and European Americans.","volume":"72","author":"Poland","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"R42-2-20210128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev.pharmtox.44.101802.121347","article-title":"The integration of pharmacokinetics and pharmacodynamics: understanding dose-response.","volume":"44","author":"Abdel-Rahman","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R43-2-20210128","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jama.287.3.356","article-title":"Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.","volume":"287","author":"Ford","year":"2002","journal-title":"JAMA"},{"key":"R44-2-20210128","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archinte.163.4.427","article-title":"The metabolic syndrome: prevalence and associated risk factors findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994.","volume":"163","author":"Park","year":"2003","journal-title":"Arch Intern Med"},{"key":"R45-2-20210128","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4088\/JCP.v62n0404","article-title":"Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.","volume":"62","author":"Basson","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R46-2-20210128","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4088\/PCC.v06n0205","article-title":"Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia.","volume":"6","author":"Kato","year":"2004","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"R47-2-20210128","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1176\/ajp.156.9.1417","article-title":"Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients.","volume":"156","author":"Cassidy","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R48-2-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0165-0327(01)00456-6","article-title":"Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use.","volume":"70","author":"Regenold","year":"2002","journal-title":"J Affect Disord"},{"key":"R49-2-20210128","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1399-5618.2004.00138.x","article-title":"Burden of general medical conditions among individuals with bipolar disorder.","volume":"6","author":"Kilbourne","year":"2004","journal-title":"Bipolar Disord"},{"key":"R50-2-20210128","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.npp.1300608","article-title":"Medical comorbidity in a bipolar outpatient clinical population.","volume":"30","author":"Beyer","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"R51-2-20210128","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2337\/diacare.21.4.518","article-title":"Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994.","volume":"21","author":"Harris","year":"1998","journal-title":"Diabetes Care"},{"key":"R52-2-20210128","first-page":"941","article-title":"Prevalence of diabetes among Hispanics-selected areas, 1998-2002.","volume":"53","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R54-2-20210128","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.2337\/diacare.27.10.2317","article-title":"Differences in diabetes prevalence, incidence, and mortality among the elderly of four racial\/ethnic groups: whites, blacks, Hispanics, and Asians.","volume":"27","author":"McBean","year":"2004","journal-title":"Diabetes Care"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e318033bd4a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T07:15:19Z","timestamp":1707722119000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-200704000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e318033bd4a","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}